Androstane 17-beta-carboxamides as androgen receptor modulators
View Patent ↗Compounds of structural formula as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue. These compounds are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, post-menopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, arthritis and joint repair, alone or in combination with other active agents.
1. A compound selected from the group consisting of: (17β)-3-oxo-N-(2-trifluoromethylphenyl)-androst-4-ene-17-carboxamide; (17β)-3-oxo-N-(3-trifluoromethylphenyl)-androst-4-ene-17-carboxamide; (17β)-3-oxo-N-(4-trifluoromethylphenyl)-androst-4-ene-17-carboxamide; (17β)-N-(2-methoxyphenyl)-3-oxoandrost-4-ene-17-carboxamide; (17β)-N-(3-methoxyphenyl)-3-oxoandrost-4-ene-17-carboxamide; (17β)-N-(4-methoxyphenyl)-3-oxoandrost-4-ene-17-carboxamide; (17β)-N-(2-chlorophenyl)-3-oxoandrost-4-ene-17-carboxamide; (17β)-N-(3-chlorophenyl)-3-oxoandrost-4-ene-17-carboxamide; (17β)-N-(4-chlorophenyl)-3-oxoandrost-4-ene-17-carboxamide; (17β)-N-(2-methylphenyl)-3-oxoandrost-4-ene-17-carboxamide; (17β)-N-(3-methylphenyl)-3-oxoandrost-4-ene-17-carboxamide; (17β)-N-(4-methylphenyl)-3-oxoandrost-4-ene-17-carboxamide; (17β)-N-(2-fluorophenyl)-3-oxoandrost-4-ene-17-carboxamide; (17β)-N-(3-fluorophenyl)-3-oxoandrost-4-ene-17-carboxamide; (17β)-N-(4-fluorophenyl)-3-oxoandrost-4-ene-17-carboxamide; (17β)-N-(2-bromophenyl)-3-oxoandrost-4-ene-17-carboxamide; (17β)-N-(2-iodophenyl)-3-oxoandrost-4-ene-17-carboxamide; (17β)-N-(3-methoxy-5-trifluoromethylphenyl)-3-oxoandrost-4-ene-17-carboxamide; (17β)-N-methyl-3-oxo-4-(2-trifluoromethylphenyl)-androst-4-ene-17-carboxamide; (17β)-4-methyl-3-oxo-N-(2-trifluoromethylphenyl)-androst-4-ene-17-carboxamide; (17β)-7-methyl-3-oxo-N-(2-trifluoromethylphenyl)-androst-4-ene-17-carboxamide; (17β)-6-methylene-3-oxo-N-(4-trifluoromethylphenyl)-androst-4-ene-17-carboxamide; (17β)-N-(4-fluorophenyl)-6-methylene-3-oxo-androst-4-ene-17-carboxamide; (17β)-6α-ethyl-3-oxo-N-(4-trifluoromethylphenyl)-androst-4-ene-17-carboxamide; (17β)-6β-ethyl-3-oxo-N-(4-trifluoromethylphenyl)-androst-4-ene-17-carboxamide; (17β)-6,6-ethyleno-3-oxo-N-(4-trifluoromethylphenyl)-androst-4-ene-17-carboxamide; (1aR,5aR,7aS,8S,10cR)-5a,7a-dimethyl-3-oxo-N-phenyl-1,1a, 3,4,5,5a,5b,6,7,7a,8,9,10,10a,10b,10c-hexadecahydro- cyclopenta[a]cyclopropa[1]phenanthrene-8-carboxamide; and (1aS,5aR,7aS,8S,10cS)-5a,7a-dimethyl-3-oxo-N-phenyl-1,1a, 3,4,5,5a,5b,6,7,7a,8,9,10,10a, 10b, 10c-hexadecahydro-cyclopenta[a]cyclopropa[1]phenanthrene-8-carboxamide; or a pharmaceutically acceptable salt thereof.
2. A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.